Highlights

  • Compumedics develops diagnostic technology for sleep, brain and ultrasonic blood-flow monitoring.
  • Its July 2026 business update reported approximately $60.3 million in FY26 shipped and invoiced revenue, up approximately 18%.
  • FY26 sales orders reached approximately $62.7 million in the July update, a measure distinct from recognised revenue.
  • Somfit and Nexus 360 software-as-a-service recurring revenue increased approximately 70% on FY25, according to the July update.
  • The company subsequently issued its FY26 preliminary results in August and annual report in September 2026.

Compumedics Limited (ASX:CMP) develops, manufactures and commercialises medical diagnostic technologies for sleep disorders, neurological monitoring and ultrasonic blood-flow applications. The July FY26 update reported approximately $60.3 million in shipped and invoiced revenue, while subsequent financial disclosures provided a fuller account of the year ended 30 June 2026.

Revenue, Orders and Reporting Milestones

In its 6 July 2026 trading update, Compumedics Limited (ASX:CMP) reported preliminary FY26 shipped and invoiced revenue of approximately $60.3 million, an increase of approximately 18% year on year. The figure was explicitly subject to audit. The same announcement disclosed approximately $62.7 million in FY26 sales orders across sleep diagnostics, neurology, magnetoencephalography (MEG) and connected platforms.

Orders reflect customer demand and do not necessarily become recognised revenue in the same period. Compumedics subsequently published its Appendix 4E preliminary final report on 25 August and its FY26 annual report on 30 September 2026; these later reports take precedence over the July trading estimate for final statutory accounts.

Connected Platforms and Recurring Software

The company’s Somfit and Nexus 360 offerings connect diagnostic equipment with data capture and clinical workflows. Compumedics Limited (ASX:CMP) said recurring software-as-a-service revenue from these platforms increased approximately 70% compared with FY25 in its July update.

Somfit is associated with sleep monitoring outside traditional laboratory settings, while Nexus 360 supports connected diagnostic data and workflow management. For Compumedics Limited (ASX:CMP), the commercial relevance lies in maintaining installed systems, supporting users and converting service utilisation into reported recurring revenue. Connected tools do not independently establish clinical superiority or a reduction in waiting times; those outcomes require separate evidence.

Equipment Deliveries and Operational Constraints

Specialist hardware remains an important component of the group’s activities. The July update noted that existing MEG orders were progressing through manufacture and shipment, including invoicing completed in June. It also stated that helium-related supply and pricing disruption affecting MEG shipments and installations had been resolved at the time of the announcement.

Compumedics Limited (ASX:CMP) also reported that manufacturing commitments for Somfit D were in place while it continued work towards a United States release. That statement describes preparation, not confirmation of a completed commercial launch or regulatory authorisation.

Financial and Commercial Considerations

The company’s product mix spans capital equipment, software subscriptions, supplies and services. Revenue timing can therefore differ between a new equipment order, a completed delivery and ongoing platform use. Compumedics Limited (ASX:CMP) has identified order conversion and recurring software as operational considerations for FY27, without making the July estimates equivalent to audited earnings.

The FY26 disclosures also show why medical-technology performance cannot be reduced to a single order figure. Production schedules, component availability, customer acceptance and clinical workflow integration all influence how commercial activity translates into reported financial results.

Key Insights

Compumedics Limited (ASX:CMP) reported higher preliminary shipped and invoiced revenue and expanding recurring software revenue in its July 2026 update. Its connected diagnostic platforms complement established equipment operations, but orders, deliveries, revenue recognition and clinical deployment remain separate milestones. The later FY26 financial reports provide the appropriate basis for final statutory comparisons.